Breast Cancer News and Research

Latest Breast Cancer News and Research

CIHR grants $2.5 million to probe impact of physical activity on breast cancer

Over the next five years, a diverse, multi-disciplinary team of researchers led by Dr. Kerry Courneya of the University of Alberta and Dr. Christine Friedenreich of Alberta Health Services will conduct a series of five large research projects to probe the impacts of physical activity on breast cancer thanks to a $2.5 million team grant over five years from the Canadian Institutes of Health Research (CIHR).

28 Jul 2010

Cytori Therapeutics receives European approval for Celution System

Cytori Therapeutics received expanded European approval (CE Mark) for its Celution System, a medical device that extracts and separates stem and regenerative cells from a patient's own fat tissue. The new indications include key medical applications such as breast reconstruction, repair of soft tissue defects, as well as the facilitation of healing certain types of wounds, such as those resulting from Crohn's disease. This broadens Cytori's ability to offer the Celution System to patients and hospitals and further supports the company's efforts to gain treatment reimbursement.

28 Jul 2010

New York Times article highlights potential value of early cancer detection technology

Manhattan Scientifics, Inc. said today that a July 20th New York Times article titled "Prone to Error: Earliest Steps to Find Cancer" highlights the potential value of the early cancer detection technology developed by Senior Scientific, LLC and licensed by Manhattan Scientifics. The story focused on widespread problems associated with incorrect diagnosis of breast cancer, and cited one study in which 90,000 women either did not have the disease or their pathologist made an error that resulted in incorrect treatment.

27 Jul 2010

Four research teams to study role of exercise in preventing, treating chronic diseases

Canadians will benefit from new insights into the link between physical activity and health as the Honourable Leona Aglukkaq, Minister of Health, today announced funding for four research teams through the Canadian Institutes of Health Research. These teams will study the effects of exercise on the body and its role in the prevention and treatment of chronic diseases including arthritis, breast cancer and heart disease.

27 Jul 2010

Abviva to receive patent for its new Mammastatin technology

Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent application Number 2.267.095 within 12 weeks

27 Jul 2010

Today's OpEds: Health reform and long-term care; Health care incentives; Reasons for optimism or repeal and replace?

Our system of long-term care does not provide adequate or coordinated human services and medical treatment for our growing aging population. … Thanks to a provision of the new health care law known as the Community Living Assistance Services and Supports program, tomorrow's continuum of care does not have to be so unforgiving. For the first time, a voluntary public insurance program will be available to help adults and families pay for long-term care services (Bruce Chernof, 7/23).

26 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

First patient enrolled in Phase 3 SyNAPSe study of BHR-100 for TBI

BHR Pharma, LLC announced today that the first patient has been enrolled in its SyNAPSe study, a global, Phase 3, pivotal trial to evaluate the safety and effectiveness of its intravenous progesterone infusion product (BHR-100) as a neuroprotective agent for treating severe (Glasgow Coma Scale scores of 4-8) traumatic brain injury patients.

23 Jul 2010

GRB7 gene drives an aggressive form of breast cancer, researchers find

Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient's treatment and enable physicians to provide a more accurate prognosis.

23 Jul 2010

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.

23 Jul 2010

New technique to detect abnormal cell circulation in non-small lung cancer

Researchers at The University of Texas M. D. Anderson Cancer Center are testing a new technique for identifying circulating genetically abnormal cells, which can lead to poor prognosis, in patients with non-small cell lung cancer.

23 Jul 2010

2010 Life Beyond Cancer Retreat invites applications

The Life Beyond Cancer Foundation is calling for applications from cancer survivors, oncology nurses, social workers, oncologists, and primary care physicians who help diagnose cancer to attend the 2010 Life Beyond Cancer Retreat. The 11th annual retreat, held Nov. 18 – 21 at Lakeway Resort & Spa in Austin, Texas, helps women rekindle their spirits, relax their minds and bodies, and rejuvenate their souls.

23 Jul 2010

African ancestry associated with triple-negative breast cancer: Study

A new study finds that African ancestry is linked to triple-negative breast cancer, a more aggressive type of cancer that has fewer treatment options.Researchers at the University of Michigan Comprehensive Cancer Center found that, among women with breast cancer, 82 percent of African women were triple negative, 26 percent of African-Americans were and 16 percent of white Americans were.

23 Jul 2010

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.

22 Jul 2010

Researchers receive $780,000 to study estrogen levels, behavior of breast cancer tumors

Researchers at the University of California, San Diego School of Medicine received nearly $780,000 from the Susan G. Komen for the Cure for two studies regarding estrogen levels and the behavior of breast cancer tumors.

22 Jul 2010

New campaign empowers, inspires women and families affected by epilepsy

A new campaign explores the roles and responsibilities women uniquely encounter when living, or caring for a loved one, with epilepsy. "Women Succeeding with Epilepsy" is a collaboration between Epilepsy Advocate and HealthyWomen to educate, empower and inspire women and families whose lives are affected by epilepsy.

22 Jul 2010